EFFEXOR XR Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Effexor Xr, and what generic alternatives are available?
Effexor Xr is a drug marketed by Upjohn and is included in one NDA.
The generic ingredient in EFFEXOR XR is venlafaxine hydrochloride. There are seventy-one drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the venlafaxine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Effexor Xr
A generic version of EFFEXOR XR was approved as venlafaxine hydrochloride by TEVA on August 3rd, 2006.
Summary for EFFEXOR XR
See drug prices for EFFEXOR XR
Recent Clinical Trials for EFFEXOR XR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AbbVie | Phase 4 |
| University of California, San Diego | Phase 2 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
Pharmacology for EFFEXOR XR
| Drug Class | Serotonin and Norepinephrine Reuptake Inhibitor |
| Mechanism of Action | Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for EFFEXOR XR
Paragraph IV (Patent) Challenges for EFFEXOR XR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| EFFEXOR XR | Extended-release Tablets | venlafaxine hydrochloride | 37.5 mg, 75 mg and 150 mg | 020699 | 1 | 2007-05-03 |
US Patents and Regulatory Information for EFFEXOR XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upjohn | EFFEXOR XR | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020699-001 | Oct 20, 1997 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| Upjohn | EFFEXOR XR | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020699-004 | Oct 20, 1997 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| Upjohn | EFFEXOR XR | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020699-002 | Oct 20, 1997 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EFFEXOR XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Upjohn | EFFEXOR XR | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020699-004 | Oct 20, 1997 | See Plans and Pricing | See Plans and Pricing |
| Upjohn | EFFEXOR XR | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020699-002 | Oct 20, 1997 | See Plans and Pricing | See Plans and Pricing |
| Upjohn | EFFEXOR XR | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020699-003 | Oct 20, 1997 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EFFEXOR XR
See the table below for patents covering EFFEXOR XR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Slovakia | 281530 | See Plans and Pricing | |
| United Kingdom | 8316646 | See Plans and Pricing | |
| Canada | 2199778 | FORMULATION DE VENLAFAXINE A LIBERATION PROLONGEE (EXTENDED RELEASE FORMULATION OF VENLAFAXINE) | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for EFFEXOR XR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0112669 | 96C0002 | Belgium | See Plans and Pricing | PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
